Christoph Franz promised to keep Roche on its current course after shareholders overwhelmingly elected him as new chairman of the Swiss drugmaker. Roche boasts an enviable list of high-margin new cancer drugs and bumper profit margins. Still, in the mid-term, Roche's margins and profits could come under pressure, as more drugmakers crowd into the hot area of cancer research and encroach on Roche's dominance. This puts more pressure on Roche to move into a new therapeutic area, having had a string of failures with medicines to treat cardiovascular disease, diabetes and schizophrenia.
via Health News Headlines - Yahoo News http://ift.tt/NQavEb
No comments:
Post a Comment